Sialyltransferase Engineering for Stable 3SL Production

Solution Overview

Problem

Current methods for producing sialylated Human Milk Oligosaccharides (HMOs), particularly 3′-sialyllactose (3′SL), face challenges such as low yields and unstable growth of production strains, due to side activities of sialyltransferases.

Innovation Solution

A genetically modified cell expressing a recombinant nucleic acid sequence encoding an α-2,3-sialyltransferase, specifically Clari1, Neigon, Poral, or PmN, is used to produce 3′SL at high yields while maintaining stable growth, even under varying growth conditions and carbon source feeding profiles.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional sialyltransferases (e.g., Nst from Neisseria meningitidis) are used for 3′SL production, then the biosynthetic pathway can be established, but the production yield is low and the growth of the production strain is unstable

Engineering Contradiction:
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent applies parameter changes by identifying and utilizing specific amino acid residues in the sialyltransferase enzyme that are critical for substrate specificity and catalytic activity. By analyzing the enzyme's active site and comparing it with known sialyltransferases, the patent modifies the enzyme's parameters (amino acid sequence, active site configuration) to achieve both high 3′SL yield and stable strain growth, resolving the contradiction between productivity and reliability

Inventive Principle:
Principle #35Parameter changes

2Productivity

If sialyltransferase activity is increased to improve 3′SL yield, then more product can be produced, but side activities cause poor growth even in the absence of substrate

Engineering Contradiction:
Core Design Contradiction:
ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by focusing the enzyme modification specifically at the active site and substrate-binding regions. By locally optimizing these critical areas while maintaining the rest of the enzyme structure intact, the patent achieves high specificity for 3′SL production, eliminating harmful side activities that would otherwise inhibit strain growth

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent converts the potential harm of high enzyme activity (which causes side reactions and poor growth) into a benefit by carefully controlling the enzyme's substrate specificity. The modified sialyltransferase is designed to be highly active toward the correct substrate (lactose) while being inactive toward other substrates that would cause harmful side activities, thus transforming high activity into a beneficial feature without the associated harms

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The approach enables the production of 3′SL with titers at least equal to, or up to 25% higher than those produced by strains expressing the Nst α-2,3-sialyltransferase, while ensuring stable growth and robustness of the production strain, making it suitable for large-scale industrial production.

Implementation Method 1

a recombinant nucleic acid sequence encoding an enzyme with α-2,3-sialyltransferase activity

Methodology Applied
Scientific EffectEnzyme catalysis: Enzyme

Implementation Method 2

the introduction of suitable glycosyltransferases to facilitate the biosynthetic production of sialylated oligosaccharides

Methodology Applied
Scientific EffectGlycosyltransferase reaction: Chemical Bonding

Implementation Method 3

the biosynthetic production of sialylated oligosaccharides

Methodology Applied
Scientific EffectBiosynthesis: Chemical Bonding

Implementation Method 4

genetically engineered cells suitable for use in said production

Methodology Applied
Scientific EffectFermentation: Fermentation

Data Source

PatentUS20250136955A1New sialyltransferases for in vivo synthesis of 3'sl
Publication Date: 2025.05.01
  • US20250136955A1 patent drawing
  • US20250136955A1 patent drawing

AI summary

The present disclosure relates to the production of sialylated Human Milk Oligosaccharides (HMOs), in particular to the biosynthetic production of 3′-sialyllactose (3′SL), and to genetically engineered cells and methods suitable for said production.